The Histopathological Changes after Neoadjuvant Theraphy for Rectal Carcinoma

Colorectal carcinomas are the third most common carcinomas in men and the second most common carcinomas in women. It has also been reported that deaths due to colorectal cancers account for approximately 9% of all cancer mortalities. Because chemotherapy, radiotherapy and/or neoadjuvant chemoradiotherapy are potentially beneficial during the preoperative period in terms of local control and sphincter-preserving surgery, they are particularly recommended for advanced stage carcinomas. With changing oncological treatments, care should be taken to ensure that the pathological staging of these cases are diligently and correctly performed, and pathological changes that may be present in the tumour after neoadjuvant therapy and staging systems have to be known.